DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer
Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic...
Gespeichert in:
Veröffentlicht in: | Cancer biology & therapy 2018-03, Vol.19 (3), p.214-221 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 221 |
---|---|
container_issue | 3 |
container_start_page | 214 |
container_title | Cancer biology & therapy |
container_volume | 19 |
creator | Kokelaar, Rory F. Jones, Huw G. Williamson, Jeremy Williams, Namor Griffiths, A. Paul Beynon, John Jenkins, Gareth J. Harris, Dean A. |
description | Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic factors.
Methods: 100 consecutive neoadjuvant-naïve patients undergoing curative surgery for rectal were classified according to the presence or absence of EMVI on histopathological examination. DNA was extracted from tumours and subjected to bisulfite conversion and methylation-specific PCR to determine CIMP status (high, intermediate, or low; according to a validated panel of 8 genes). CIMP status was correlated with EMVI status, histopathological, clinical, and demographic variables, in addition to overall (OS) and disease free (DFS) survival.
Results: 51 patients were characterised as CIMP-low, 48 CIMP-intermediate, and one patient CIMP-high. EMVI-positivity was associated with CIMP-intermediate epigenotype (p < 0.001). Patients with EMVI-positive tumours were found to have significantly more advanced disease by pT, pN, and pAJCC categorisation (p = 0.002, p < 0.001, and = p < 0.001, respectively). EMVI-positivity was significantly associated with the requirement for adjuvant chemotherapy (p < 0.001), and worse DFS but not OS (p = 0.012 and p = 0.052).
Conclusions: Given the association between CIMP-intermediate epigenotype and EMVI-positivity, and the subsequent disadvantage in pathological stage, requirement for adjuvant therapy and worse survival, tumour epigenotyping could potentially play an important role in personalising patients' cancer care. Further work is required to understand the mechanisms that underlie the observed effect, with the hope that they may provide novel opportunities for intervention and inform treatment decisions in rectal cancer. |
doi_str_mv | 10.1080/15384047.2017.1416933 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_29260978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1979172507</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-796f6a56690dbf6015579d090c9308864dce2e1470c4794783e844c0ed22d09a3</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0EoqXlJ4C8LIsM14_4sUFUpUClApu2GxaW6ziMkRNP7aQw_x5HM61gw8rXut8959oHoVcEVgQUvCUtUxy4XFEgckU4EZqxJ-iQtG3bqFaKp0vNVLNAB-hFKT8BqKRCP0cHVFMBWqpD9P3D11O83m58Hvy03kY7hTRiW7DFm-y74KaUceqx_z1lO8zZRnxvi5ujzTiMtVzwk_MvNxdv6h1n76aKODs6n4_Rs97G4l_uzyN0_fH86uxzc_nt08XZ6WXjuFBTI7XohW2F0NDd9gLqC6TuQIPTDJQSvHOeesIlOC41l4p5xbkD31FaMcuO0Lud7ma-HXylx7prNJscBpu3Jtlg_u2MYW1-pHtTfYAJUgVO9gI53c2-TGYIxfkY7ejTXAzRUhNJW5AVbXeoy6mU7PtHGwJmCcY8BGOWYMw-mDr3-u8dH6cekqjA-x0Qxj7lwf5KOXZmstuYcp_rf4Zi2P89_gACXZ0r</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1979172507</pqid></control><display><type>article</type><title>DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kokelaar, Rory F. ; Jones, Huw G. ; Williamson, Jeremy ; Williams, Namor ; Griffiths, A. Paul ; Beynon, John ; Jenkins, Gareth J. ; Harris, Dean A.</creator><creatorcontrib>Kokelaar, Rory F. ; Jones, Huw G. ; Williamson, Jeremy ; Williams, Namor ; Griffiths, A. Paul ; Beynon, John ; Jenkins, Gareth J. ; Harris, Dean A.</creatorcontrib><description>Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic factors.
Methods: 100 consecutive neoadjuvant-naïve patients undergoing curative surgery for rectal were classified according to the presence or absence of EMVI on histopathological examination. DNA was extracted from tumours and subjected to bisulfite conversion and methylation-specific PCR to determine CIMP status (high, intermediate, or low; according to a validated panel of 8 genes). CIMP status was correlated with EMVI status, histopathological, clinical, and demographic variables, in addition to overall (OS) and disease free (DFS) survival.
Results: 51 patients were characterised as CIMP-low, 48 CIMP-intermediate, and one patient CIMP-high. EMVI-positivity was associated with CIMP-intermediate epigenotype (p < 0.001). Patients with EMVI-positive tumours were found to have significantly more advanced disease by pT, pN, and pAJCC categorisation (p = 0.002, p < 0.001, and = p < 0.001, respectively). EMVI-positivity was significantly associated with the requirement for adjuvant chemotherapy (p < 0.001), and worse DFS but not OS (p = 0.012 and p = 0.052).
Conclusions: Given the association between CIMP-intermediate epigenotype and EMVI-positivity, and the subsequent disadvantage in pathological stage, requirement for adjuvant therapy and worse survival, tumour epigenotyping could potentially play an important role in personalising patients' cancer care. Further work is required to understand the mechanisms that underlie the observed effect, with the hope that they may provide novel opportunities for intervention and inform treatment decisions in rectal cancer.</description><identifier>ISSN: 1538-4047</identifier><identifier>EISSN: 1555-8576</identifier><identifier>DOI: 10.1080/15384047.2017.1416933</identifier><identifier>PMID: 29260978</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>CIMP ; Epigenetics ; Original ; Rectal Cancer ; Vascular Invasion</subject><ispartof>Cancer biology & therapy, 2018-03, Vol.19 (3), p.214-221</ispartof><rights>2018 Taylor & Francis Group, LLC 2018</rights><rights>2018 Taylor & Francis Group, LLC 2018 Taylor & Francis Group, LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-796f6a56690dbf6015579d090c9308864dce2e1470c4794783e844c0ed22d09a3</citedby><cites>FETCH-LOGICAL-c468t-796f6a56690dbf6015579d090c9308864dce2e1470c4794783e844c0ed22d09a3</cites><orcidid>0000-0002-1076-7294</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790361/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790361/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29260978$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kokelaar, Rory F.</creatorcontrib><creatorcontrib>Jones, Huw G.</creatorcontrib><creatorcontrib>Williamson, Jeremy</creatorcontrib><creatorcontrib>Williams, Namor</creatorcontrib><creatorcontrib>Griffiths, A. Paul</creatorcontrib><creatorcontrib>Beynon, John</creatorcontrib><creatorcontrib>Jenkins, Gareth J.</creatorcontrib><creatorcontrib>Harris, Dean A.</creatorcontrib><title>DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer</title><title>Cancer biology & therapy</title><addtitle>Cancer Biol Ther</addtitle><description>Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic factors.
Methods: 100 consecutive neoadjuvant-naïve patients undergoing curative surgery for rectal were classified according to the presence or absence of EMVI on histopathological examination. DNA was extracted from tumours and subjected to bisulfite conversion and methylation-specific PCR to determine CIMP status (high, intermediate, or low; according to a validated panel of 8 genes). CIMP status was correlated with EMVI status, histopathological, clinical, and demographic variables, in addition to overall (OS) and disease free (DFS) survival.
Results: 51 patients were characterised as CIMP-low, 48 CIMP-intermediate, and one patient CIMP-high. EMVI-positivity was associated with CIMP-intermediate epigenotype (p < 0.001). Patients with EMVI-positive tumours were found to have significantly more advanced disease by pT, pN, and pAJCC categorisation (p = 0.002, p < 0.001, and = p < 0.001, respectively). EMVI-positivity was significantly associated with the requirement for adjuvant chemotherapy (p < 0.001), and worse DFS but not OS (p = 0.012 and p = 0.052).
Conclusions: Given the association between CIMP-intermediate epigenotype and EMVI-positivity, and the subsequent disadvantage in pathological stage, requirement for adjuvant therapy and worse survival, tumour epigenotyping could potentially play an important role in personalising patients' cancer care. Further work is required to understand the mechanisms that underlie the observed effect, with the hope that they may provide novel opportunities for intervention and inform treatment decisions in rectal cancer.</description><subject>CIMP</subject><subject>Epigenetics</subject><subject>Original</subject><subject>Rectal Cancer</subject><subject>Vascular Invasion</subject><issn>1538-4047</issn><issn>1555-8576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kUtv1DAUhS0EoqXlJ4C8LIsM14_4sUFUpUClApu2GxaW6ziMkRNP7aQw_x5HM61gw8rXut8959oHoVcEVgQUvCUtUxy4XFEgckU4EZqxJ-iQtG3bqFaKp0vNVLNAB-hFKT8BqKRCP0cHVFMBWqpD9P3D11O83m58Hvy03kY7hTRiW7DFm-y74KaUceqx_z1lO8zZRnxvi5ujzTiMtVzwk_MvNxdv6h1n76aKODs6n4_Rs97G4l_uzyN0_fH86uxzc_nt08XZ6WXjuFBTI7XohW2F0NDd9gLqC6TuQIPTDJQSvHOeesIlOC41l4p5xbkD31FaMcuO0Lud7ma-HXylx7prNJscBpu3Jtlg_u2MYW1-pHtTfYAJUgVO9gI53c2-TGYIxfkY7ejTXAzRUhNJW5AVbXeoy6mU7PtHGwJmCcY8BGOWYMw-mDr3-u8dH6cekqjA-x0Qxj7lwf5KOXZmstuYcp_rf4Zi2P89_gACXZ0r</recordid><startdate>20180304</startdate><enddate>20180304</enddate><creator>Kokelaar, Rory F.</creator><creator>Jones, Huw G.</creator><creator>Williamson, Jeremy</creator><creator>Williams, Namor</creator><creator>Griffiths, A. Paul</creator><creator>Beynon, John</creator><creator>Jenkins, Gareth J.</creator><creator>Harris, Dean A.</creator><general>Taylor & Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1076-7294</orcidid></search><sort><creationdate>20180304</creationdate><title>DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer</title><author>Kokelaar, Rory F. ; Jones, Huw G. ; Williamson, Jeremy ; Williams, Namor ; Griffiths, A. Paul ; Beynon, John ; Jenkins, Gareth J. ; Harris, Dean A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-796f6a56690dbf6015579d090c9308864dce2e1470c4794783e844c0ed22d09a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>CIMP</topic><topic>Epigenetics</topic><topic>Original</topic><topic>Rectal Cancer</topic><topic>Vascular Invasion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kokelaar, Rory F.</creatorcontrib><creatorcontrib>Jones, Huw G.</creatorcontrib><creatorcontrib>Williamson, Jeremy</creatorcontrib><creatorcontrib>Williams, Namor</creatorcontrib><creatorcontrib>Griffiths, A. Paul</creatorcontrib><creatorcontrib>Beynon, John</creatorcontrib><creatorcontrib>Jenkins, Gareth J.</creatorcontrib><creatorcontrib>Harris, Dean A.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer biology & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kokelaar, Rory F.</au><au>Jones, Huw G.</au><au>Williamson, Jeremy</au><au>Williams, Namor</au><au>Griffiths, A. Paul</au><au>Beynon, John</au><au>Jenkins, Gareth J.</au><au>Harris, Dean A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer</atitle><jtitle>Cancer biology & therapy</jtitle><addtitle>Cancer Biol Ther</addtitle><date>2018-03-04</date><risdate>2018</risdate><volume>19</volume><issue>3</issue><spage>214</spage><epage>221</epage><pages>214-221</pages><issn>1538-4047</issn><eissn>1555-8576</eissn><abstract>Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic factors.
Methods: 100 consecutive neoadjuvant-naïve patients undergoing curative surgery for rectal were classified according to the presence or absence of EMVI on histopathological examination. DNA was extracted from tumours and subjected to bisulfite conversion and methylation-specific PCR to determine CIMP status (high, intermediate, or low; according to a validated panel of 8 genes). CIMP status was correlated with EMVI status, histopathological, clinical, and demographic variables, in addition to overall (OS) and disease free (DFS) survival.
Results: 51 patients were characterised as CIMP-low, 48 CIMP-intermediate, and one patient CIMP-high. EMVI-positivity was associated with CIMP-intermediate epigenotype (p < 0.001). Patients with EMVI-positive tumours were found to have significantly more advanced disease by pT, pN, and pAJCC categorisation (p = 0.002, p < 0.001, and = p < 0.001, respectively). EMVI-positivity was significantly associated with the requirement for adjuvant chemotherapy (p < 0.001), and worse DFS but not OS (p = 0.012 and p = 0.052).
Conclusions: Given the association between CIMP-intermediate epigenotype and EMVI-positivity, and the subsequent disadvantage in pathological stage, requirement for adjuvant therapy and worse survival, tumour epigenotyping could potentially play an important role in personalising patients' cancer care. Further work is required to understand the mechanisms that underlie the observed effect, with the hope that they may provide novel opportunities for intervention and inform treatment decisions in rectal cancer.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>29260978</pmid><doi>10.1080/15384047.2017.1416933</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1076-7294</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1538-4047 |
ispartof | Cancer biology & therapy, 2018-03, Vol.19 (3), p.214-221 |
issn | 1538-4047 1555-8576 |
language | eng |
recordid | cdi_pubmed_primary_29260978 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | CIMP Epigenetics Original Rectal Cancer Vascular Invasion |
title | DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A48%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DNA%20hypermethylation%20as%20a%20predictor%20of%20extramural%20vascular%20invasion%20(EMVI)%20in%20rectal%20cancer&rft.jtitle=Cancer%20biology%20&%20therapy&rft.au=Kokelaar,%20Rory%20F.&rft.date=2018-03-04&rft.volume=19&rft.issue=3&rft.spage=214&rft.epage=221&rft.pages=214-221&rft.issn=1538-4047&rft.eissn=1555-8576&rft_id=info:doi/10.1080/15384047.2017.1416933&rft_dat=%3Cproquest_pubme%3E1979172507%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1979172507&rft_id=info:pmid/29260978&rfr_iscdi=true |